James Yao
詹姆斯·姚
MD
Professor and Chair, Department of Gastrointestinal Medical Oncology胃肠肿瘤内科学系主任兼教授
👥Biography 个人简介
Dr. James Yao is a leading authority on pancreatic neuroendocrine tumors at MD Anderson Cancer Center. He led pivotal phase III trials establishing everolimus and sunitinib as standard-of-care treatments for advanced pancreatic NET, fundamentally changing the therapeutic landscape.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Everolimus in Pancreatic NET
Led the RADIANT-3 phase III trial demonstrating everolimus doubled progression-free survival in advanced pancreatic NET, securing FDA approval and establishing a new standard of care.
Targeted Therapy Development
Contributed to the clinical evaluation of sunitinib and other targeted agents in NET, advancing the field from cytotoxic chemotherapy toward molecularly directed treatment strategies.
Representative Works 代表性著作
Everolimus for advanced pancreatic neuroendocrine tumors (RADIANT-3)
New England Journal of Medicine (2011)
Landmark phase III trial showing everolimus significantly prolonged progression-free survival in advanced pancreatic NET, leading to FDA approval.
One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
Journal of Clinical Oncology (2008)
Comprehensive SEER analysis defining NET epidemiology and prognosis, cited extensively as a foundational reference in the field.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Matthew Kulke
Boston Medical Center / Boston University
Emily Bergsland
University of California, San Francisco (UCSF)
Eric Liu
Rocky Mountain Cancer Centers
Marianne Pavel
Charité – Universitätsmedizin Berlin
关注 詹姆斯·姚 的研究动态
Follow James Yao's research updates
留下邮箱，当我们发布与 James Yao（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment